IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR-INHIBITORS Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Kavanaugh, A
  • Marzo-Ortega, H
  • Vender, Ronald
  • Birt, J
  • Adams, D
  • Benichou, O
  • Lin, C-Y
  • Nash, P

publication date

  • May 1, 2018